STAT’s biotech briefing places a Novartis multiple sclerosis development at the center of its coverage. The headline describes the development as a win involving a BTK inhibitor, but the supplied article does not provide trial results or other supporting details.
The item appears in The Readout, STAT’s biotech newsletter, alongside updates on drug pricing, vaccine development and other industry activity. The briefing also says Alumis reported that its experimental lupus treatment did not meet the efficacy goals of a mid-stage clinical trial.
A separate item says President Trump announced that his administration had reached additional drug-pricing agreements with biotechs. Those agreements were described as joining 17 deals the administration had previously made with companies.
The page promotes that pricing item as an exclusive story for STAT subscribers. The article’s related coverage also includes an item about speeding up development of an mRNA flu vaccine.
Other linked topics include a pregnancy hormone and cardiovascular treatment, radiopharmaceuticals experts working in cancer therapy, and a boost for mRNA after a difficult period. STAT identifies Elaine Chen and Helen Branswell as the writers of the briefing, with Chen covering biotechnology and Branswell covering infectious diseases and vaccine development.
The page offers The Readout newsletter as a way for readers to follow science and politics shaping biotech. Beyond the headline characterization of the Novartis development, the supplied material does not state how the treatment performed, what regulator was involved or what happens next.